Background: The MGuard (Inspire MD, Tel Aviv, Israel) is a bare-metal polyethylene terephthalate micronet mesh–covered stent that was designed to prevent distal embolization of thrombus or friable debris causing impaired myocardial perfusion and adverse clinical events.
Objective: To evaluate the procedure and long term outcomes undergoing MGuard stenting at our center.
Methods & Results: The MGuard stent was utilized in 163 consecutive patients, 67% patients had SVG lesions and 33% were treated for native arteries during MI. The mean age was 70 years and 83% were males. The clinical presentation was STEMI in 33% and NSTEMI/UA in 60% of patients, 46% patients had DM and 28% sustained some degree of renal insufficiency. The mean stent length was 30±18 mm in vessels with a mean diameter of 3.4±0.5 mm. Clinical outcomes are shown in the Table:
| |
One year
|
|
|
Outcomes
|
Native=54
|
VG=109
|
|
Death
|
1.9%
|
10.4%
|
|
MI
|
1.9%
|
14%
|
|
Definite Stent Thrombosis
|
1.9%
|
1.8%
|
|
MACE
|
11%
|
29%
|
| |
|
|
|
Target Vessel Revascularization
|
5.6%
|
15%
|
|
CABG
|
3.7%
|
0.9%
|
Conclusions: In suitable patients, the MGuard stent seems to be a viable treatment strategy in PCI management of thrombus and\or friable atheromatous containing lesions within SVG and/or native coronary vessels during the course of MI.
